Imberti L, Magro P, Sottini A, Quaresima V, Castelli F, Quiros-Roldan E
Immun Inflamm Dis. 2023; 11(11):e1056.
PMID: 38018592
PMC: 10664390.
DOI: 10.1002/iid3.1056.
Rich S, Nasta P, Quiros-Roldan E, Fusco P, Tondinelli A, Costa C
Eur J Med Res. 2023; 28(1):292.
PMID: 37596688
PMC: 10436514.
DOI: 10.1186/s40001-023-01276-3.
Fusco P, Nasta P, Quiros-Roldan E, Tondinelli A, Costa C, Fornabaio C
Viruses. 2023; 15(4).
PMID: 37112904
PMC: 10145592.
DOI: 10.3390/v15040924.
Quiros-Roldan E, Magro P, Raffetti E, Izzo I, Borghetti A, Lombardi F
BMC Infect Dis. 2018; 18(1):285.
PMID: 29940869
PMC: 6020212.
DOI: 10.1186/s12879-018-3198-2.
Quiros-Roldan E, Castelli F, Lanza P, Pezzoli C, Vezzoli M, Biasiotto G
J Transl Med. 2017; 15(1):256.
PMID: 29258550
PMC: 5735890.
DOI: 10.1186/s12967-017-1358-6.
Role of systemic inflammation scores for prediction of clinical outcomes in patients treated with atazanavir not boosted by ritonavir in the Italian MASTER cohort.
Postorino M, Prosperi M, Foca E, Quiros-Roldan E, Di Filippo E, Maggiolo F
BMC Infect Dis. 2017; 17(1):212.
PMID: 28298195
PMC: 5353877.
DOI: 10.1186/s12879-017-2322-z.
Systemic inflammation-based scores and mortality for all causes in HIV-infected patients: a MASTER cohort study.
Raffetti E, Donato F, Casari S, Castelnuovo F, Sighinolfi L, Bandera A
BMC Infect Dis. 2017; 17(1):193.
PMID: 28264665
PMC: 5339992.
DOI: 10.1186/s12879-017-2280-5.
B- and T-lymphocyte number and function in HIV/HIV lymphoma patients treated with high-dose chemotherapy and autologous bone marrow transplantation.
Bertoli D, Re A, Chiarini M, Sottini A, Serana F, Giustini V
Sci Rep. 2016; 6:37995.
PMID: 27905485
PMC: 5131356.
DOI: 10.1038/srep37995.
The burden of chronic diseases and cost-of-care in subjects with HIV infection in a Health District of Northern Italy over a 12-year period compared to that of the general population.
Quiros-Roldan E, Magoni M, Raffetti E, Donato F, Scarcella C, Paraninfo G
BMC Public Health. 2016; 16(1):1146.
PMID: 27829390
PMC: 5103392.
DOI: 10.1186/s12889-016-3804-4.
Risk of Chronic Kidney Disease among Patients Developing Mild Renal Impairment during Tenofovir-Containing Antiretroviral Treatment.
Lapadula G, Bernasconi D, Casari S, Maggiolo F, Cauda R, Di Pietro M
PLoS One. 2016; 11(9):e0162320.
PMID: 27632369
PMC: 5025011.
DOI: 10.1371/journal.pone.0162320.
Exploratory Analysis for the Evaluation of Estimated Glomerular Filtration Rate, Cholesterol and Triglycerides after Switching from Tenofovir/Emtricitabine plus Atazanavir/Ritonavir (ATV/r) to Abacavir/Lamivudine plus ATV/r in Patients with....
Postorino M, Quiros-Roldan E, Maggiolo F, Di Giambenedetto S, Ladisa N, Lapadula G
Open AIDS J. 2016; 10:136-43.
PMID: 27563366
PMC: 4968049.
DOI: 10.2174/1874613601610010136.
The risk of late or advanced presentation of HIV infected patients is still high, associated factors evolve but impact on overall mortality is vanishing over calendar years: results from the Italian MASTER Cohort.
Raffetti E, Postorino M, Castelli F, Casari S, Castelnuovo F, Maggiolo F
BMC Public Health. 2016; 16(1):878.
PMID: 27557878
PMC: 4997689.
DOI: 10.1186/s12889-016-3477-z.
Liver fibrosis progression and clinical outcomes are intertwined: role of CD4+ T-cell count and NRTI exposure from a large cohort of HIV/HCV-coinfected patients with detectable HCV-RNA: A MASTER cohort study.
Foca E, Fabbiani M, Prosperi M, Quiros Roldan E, Castelli F, Maggiolo F
Medicine (Baltimore). 2016; 95(29):e4091.
PMID: 27442636
PMC: 5265753.
DOI: 10.1097/MD.0000000000004091.
Incidence and predictors of cardiovascular disease, chronic kidney disease, and diabetes in HIV/HCV-coinfected patients who achieved sustained virological response.
Leone S, Prosperi M, Costarelli S, Nasta P, Maggiolo F, Di Giambenedetto S
Eur J Clin Microbiol Infect Dis. 2016; 35(9):1511-20.
PMID: 27272121
DOI: 10.1007/s10096-016-2692-y.
